Matinas BioPharma (MTNB) Fireside Chat summary

Introduction and agenda

• The discussion focused on the potential of MAT2203, an oral antifungal under development, and its role in treating invasive fungal infections.

• The agenda included market landscape, current therapies, MAT2203's differentiation, and clinical trial insights.

Background and experience of the speaker

• Dr. Perlin is Chief Scientific Officer at the Center for Discovery and Innovation, with 30 years' experience in antifungal research.

• He is Editor-in-Chief of the Journal of Fungi and serves on the Global Action Fund for Fungal Infections, collaborating with WHO.

• Dr. Perlin disclosed no financial conflicts related to MAT2203.

Current industry trends

• Invasive fungal infections have high mortality rates and limited treatment options, with increasing drug resistance, especially to azoles.

• Amphotericin B remains a mainstay due to broad-spectrum activity, but toxicity and IV-only administration limit its use.

• There is significant unmet need for safer, more convenient antifungal therapies.